The Drug Discovery, Delivery and Translational Therapeutics (DT) Program is the most diverse scientific program, including members from five different colleges. The DT Program’s collaborative physicians and scientists are devoted to driving discovery and translation through the drug development pipeline. The overarching goal of the DT Program is to discover, develop, and evaluate novel anticancer agents and biomarkers with a focus on targeted therapies of relevance to our catchment population.
Program members use their particular scientific expertise to help the program follow through on three goals: 1) identify catchment area specific targets and biomarkers; 2) discover and develop new anticancer agents; and 3) develop and participate in early phase clinical trials.
The DT Program’s regular meetings are used to discuss funding opportunities, updates from Markey Shared Resource Facilities and to develop plans for grant applications. The program also has an annual retreat.
DT Program members are active participants in the cancer center’s Breast Cancer Translational Working Group, the Head and Neck Translational Working Group, the Immunotherapy Translational Working Group, and the Lung Cancer Translational Working Group. DT members are also critical to the cancer center’s Molecular Tumor Board, led by DT members Jill Kolesar and Rachel Miller. In addition, DT members participate in the cancer center’s target modulator development groups, spanning focus areas from 4E-BP1 to IDH-1.